CardioVascular and Interventional Radiology

, Volume 38, Issue 2, pp 361–371 | Cite as

Small Versus Large-Sized Drug-Eluting Beads (DEBIRI) for the Treatment of Hepatic Colorectal Metastases: A Propensity Score Matching Analysis

  • Olaguoke K. Akinwande
  • Prejesh Philips
  • Petr Duras
  • Stefan Pluntke
  • Charles Scoggins
  • Robert C. G. Martin
Clinical Investigation



To compare the feasibility, safety, and efficacy with small and large irinotecan drug-eluting beads (DEBIRI) for treating hepatic colorectal metastases.


Using our prospectively maintained, multi-center, intra-arterial therapy registry, we identified 196 patients treated with a combination of large beads (100–300 to 500–700 μm) and patients treated with a combination of small beads (70–150 to 100–300 μm). To minimize selection bias, a propensity score analysis was performed to compare both groups.


Unadjusted analysis consisted of 196 and 30 patients treated with large and small beads, respectively. The adjusted analysis consisted of 19 patients each. Unadjusted analysis showed decreased all-grade (p = <0.001) and high-grade adverse effects (p = 0.02) in the small bead group, with a persisting trend toward decreased overall side effects in the adjusted analysis favoring small beads (p = 0.09) The adjusted analysis showed the percentage dose delivered (delivered dose/intended dose) was significantly greater in the small bead group compared to the large bead group (96 vs 79 %; p = 0.005). There were also a lower percentage of treatments terminating in complete stasis in the adjusted analysis (0.0035). Adjusted analysis also showed increased objective response rate (ORR) at 12 months (p = 0.04), with a corresponding trend also seen in the unadjusted analysis (0.09).


Smaller beads result in increased dose delivery probably due to less propensity to reach complete stasis. It may also lead to more durable long-term efficacy. Smaller beads also demonstrate similarly low toxicity compared to large-sized beads with a trend toward less toxicity.


Interventional oncology Chemoembolization Embolization Clinical practice Liver 


Conflict of Interest

Robert CG Martin is a consultant for Biocompatibles. Olaguoke Akinwande, Prejesh Philips, Petr Duras, Stefan Pluntke, and Charles Scoggins have nothing to disclose.

Statement of Informed Consent

Informed consent was obtained from all individual participants included in the study

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Poggi G, Quaretti P, Minoia C, Bernardo G, Bonora MR, Gaggeri R et al (2008) Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 28(6B):3835–3842 PubMed PMID: 19192637PubMedGoogle Scholar
  2. 2.
    Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM et al (2011) Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117(2):343–352. doi: 10.1002/cncr.25387 PubMed PMID: 20830766CrossRefPubMedGoogle Scholar
  3. 3.
    Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL et al (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 247(2):507–515. doi: 10.1148/radiol.2472062029 PubMed PMID: 18349311CrossRefPubMedGoogle Scholar
  4. 4.
    Goere D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F et al (2010) Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 251(4):686–691. doi: 10.1097/SLA.0b013e3181d35983 PubMed PMID: 20224373CrossRefPubMedGoogle Scholar
  5. 5.
    van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D et al (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 27(25):4089–4095. doi: 10.1200/JCO.2008.20.8116 PubMed PMID: 19652069CrossRefGoogle Scholar
  6. 6.
    Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). Off J Am Soc Clin Oncol 24(9):1395–1403. doi: 10.1200/JCO.2005.03.8166 PubMed PMID: 16505413CrossRefGoogle Scholar
  7. 7.
    Bavisotto LM, Patel NH, Althaus SJ, Coldwell DM, Nghiem HV, Thompson T et al (1999) Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res Off J Am Assoc Cancer Res 5(1):95–109 PubMed PMID: 9918207Google Scholar
  8. 8.
    Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M (2007) Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 17(4):1025–1034. doi: 10.1007/s00330-006-0372-5 PubMed PMID: 16944163CrossRefPubMedGoogle Scholar
  9. 9.
    Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395 PubMed PMID: 22493375PubMedGoogle Scholar
  10. 10.
    Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18(1):192–198. doi: 10.1245/s10434-010-1288-5 PubMed PMID: 20740319CrossRefPubMedGoogle Scholar
  11. 11.
    Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G (2013) Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33(5):2077–2083 PubMed PMID: 23645758PubMedGoogle Scholar
  12. 12.
    Martin R, Irurzun J, Munchart J, Trofimov I, Scupchenko A, Tatum C et al (2011) Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. Korean J Hepatol 17(1):51–60. doi: 10.3350/kjhep.2011.17.1.51 PubMed PMID: 21494078; PubMed Central PMCID: PMC3304625CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S et al (2013) Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. J Vasc Interv Radiol JVIR 24(3):301–306. doi: 10.1016/j.jvir.2012.11.023 PubMed PMID: 23380737CrossRefGoogle Scholar
  14. 14.
    Lee KH, Liapi E, Vossen JA, Buijs M, Ventura VP, Georgiades C et al (2008) Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol JVIR 19(10):1490–1496. doi: 10.1016/j.jvir.2008.06.008 PubMed PMID: 18755602; PubMed Central PMCID: PMC2747287CrossRefGoogle Scholar
  15. 15.
    Namur J, Citron SJ, Sellers MT, Dupuis MH, Wassef M, Manfait M et al (2011) Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol 55(6):1332–1338. doi: 10.1016/j.jhep.2011.03.024 PubMed PMID: 21703190CrossRefPubMedGoogle Scholar
  16. 16.
    Joffe MM, Rosenbaum PR (1999) Invited commentary: propensity scores. Am J Epidemiol 150(4):327–333 PubMed PMID: 10453808CrossRefPubMedGoogle Scholar
  17. 17.
    Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM et al (2010) Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Interv Radiol 33(5):960–966. doi: 10.1007/s00270-010-9937-4 PubMed PMID: 20661569CrossRefGoogle Scholar
  18. 18.
    Martin RC, Joshi J, Robbins K, Tomalty D, O’Hara R, Tatum C (2009) Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009:539795. doi: 10.1155/2009/539795 PubMed PMID: 19888427; PubMed Central PMCID: PMC2771155CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Lewandowski RJ, Wang D, Gehl J, Atassi B, Ryu RK, Sato K et al (2007) A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol JVIR 18(10):1249–1257. doi: 10.1016/j.jvir.2007.06.028 PubMed PMID: 17911515CrossRefGoogle Scholar
  20. 20.
    Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759. doi: 10.1200/JCO.2006.07.3049 PubMed PMID: 17470865CrossRefPubMedGoogle Scholar
  21. 21.
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698–711. doi: 10.1093/jnci/djn134 PubMed PMID: 18477802CrossRefPubMedGoogle Scholar
  22. 22.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi: 10.1016/j.ejca.2008.10.026 PubMed PMID: 19097774CrossRefPubMedGoogle Scholar
  23. 23.
    Haviland A, Nagin DS, Rosenbaum PR (2007) Combining propensity score matching and group-based trajectory analysis in an observational study. Psychol Methods 12(3):247–267. doi: 10.1037/1082-989X.12.3.247 PubMed PMID: 17784793CrossRefPubMedGoogle Scholar
  24. 24.
    Braitman LE, Rosenbaum PR (2002) Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 137(8):693–695 PubMed PMID: 12379071CrossRefPubMedGoogle Scholar
  25. 25.
    Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ (2003) Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA J Am Med Assoc 290(24):3207–3214. doi: 10.1001/jama.290.24.3207 PubMed PMID: 14693873CrossRefGoogle Scholar
  26. 26.
    Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 5(9):1100–1108. doi: 10.1016/j.cgh.2007.04.021 PubMed PMID: 17627902Google Scholar
  27. 27.
    Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481. doi: 10.1016/j.jhep.2006.10.020 PubMed PMID: 17239480CrossRefPubMedGoogle Scholar
  28. 28.
    Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 31(2):269–280. doi: 10.1007/s00270-007-9226-z PubMed PMID: 17999110CrossRefGoogle Scholar
  29. 29.
    Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33(1):41–52. doi: 10.1007/s00270-009-9711-7 PubMed PMID: 19908093; PubMed Central PMCID: PMC2816794CrossRefGoogle Scholar
  30. 30.
    Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN et al (2014) Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer 13(1):27–36. doi: 10.1016/j.clcc.2013.11.010 PubMed PMID: 24370352CrossRefPubMedGoogle Scholar
  31. 31.
    Dreher MR, Sharma KV, Woods DL, Reddy G, Tang Y, Pritchard WF, et al. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. Journal of vascular and interventional radiology : JVIR. 23(2):257-64. doi: 10.1016/j.jvir.2011.10.019. PubMed PMID: 22178039; PubMed Central PMCID: PMC3360470
  32. 32.
    Lencioni R, Aliberti C, de Baere T, Garcia-Monaco R, Narayanan G, O’Grady E et al (2014) Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol JVIR 25(3):365–369. doi: 10.1016/j.jvir.2013.11.027 PubMed PMID: 24581461CrossRefGoogle Scholar
  33. 33.
    Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127(8 Pt 2):757–763CrossRefPubMedGoogle Scholar
  34. 34.
    Rubin DB, Thomas N (1996) Matching using estimated propensity scores: relating theory to practice. Biometrics 52(1):249–264CrossRefPubMedGoogle Scholar
  35. 35.
    Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 342(25):1887–1892. doi: 10.1056/NEJM200006223422507 PubMed PMID: 10861325; PubMed Central PMCID: PMC1557642CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. New Engl J Med 342(25):1878–1886. doi: 10.1056/NEJM200006223422506 PubMed PMID: 10861324CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2014

Authors and Affiliations

  • Olaguoke K. Akinwande
    • 1
    • 2
  • Prejesh Philips
    • 3
  • Petr Duras
    • 4
  • Stefan Pluntke
    • 5
  • Charles Scoggins
    • 3
  • Robert C. G. Martin
    • 3
  1. 1.Department of Interventional RadiologyUniversity of Louisville HospitalLouisvilleUSA
  2. 2.Department of Interventional RadiologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  3. 3.Division of Surgical Oncology, Department of SurgeryUniversity of LouisvilleLouisvilleUSA
  4. 4.Fakultní nemocnice PlzeňPlzeňCzech Republic
  5. 5.Onkologe bei Kliniken Essen-MitteEssenGermany

Personalised recommendations